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1  |  INTRODUC TION
In this review, we examine hair follicle miniaturisation and how func-
tional changes to the follicle and its environment might explain the 
variable nature of current treatment success and provide new insights 
for those researchers developing new hair regeneration strategies.1 
It is well established that common balding in men (male pattern hair 
loss, MPHL) and women (female pattern hair loss, FPHL)— referred 
here as patterned hair loss (PHL)— involves a progressive regression 
in the fundamental hair variables (density, growth phase, diameter 
and growth rate) which involves androgen initiation in susceptible 
individuals.2- 6 In 1942, James Hamilton observed that following 
androgen ablation no reversal of miniaturised hair occurred in men 
with established PHL and we have previously reported that current 
medical treatments do not reverse miniaturisation.4– 6 These ob-
servations question why miniaturised terminal hair follicles cannot 
revert to their former terminal status. We revisit a 50- year- old ob-
servation initially reported by Arao and Perkins in 19697 and again by 
Pinkus in 19788 that an “elastin body” comprising dense elastic tis-
sue deposited beneath the follicle after each cycle, might explain the 
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Abstract
Pattern hair loss (PHL) is a chronic regressive condition of the scalp, where follicular 
miniaturisation and decreased scalp hair coverage occurs in affected areas. In all PHL 
cases, there is a measurable progressive shortening of the terminal hair growth du-
ration, along with reduced linear growth rates. In both genders, PHL initially shows 
an increase in short telogen hairs ≤30 mm in length, reflecting a cycle completion of 
under 6 months in affected terminal hair follicles. To understand the miniaturisation 
process, we re- examine the dynamics of miniaturisation and ask the question, “why 
do miniaturised hair follicles resist treatment?” In the light of recent developments in 
relation to hair regeneration, we looked back in the older literature for helpful clues 
“lost to time” and reprise a 1978 Hermann Pinkus observation of an array of elastin 
deposits beneath the dermal papilla following subsequent anagen/telogen transitions 
in male balding, originally described by Arao and Perkins who concluded that these 
changes provide a “morphologic marker of the entire biologic process in the balding 
scalp.” Thus, we have reviewed the role of the elastin- like bodies in hair pathology 
and we propose that alterations in elastin architecture may contribute to the failure 
of vellus- like hair reverting back to their terminal status and may indicate a new area 
for therapeutic intervention.
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irreversibility of follicle miniaturisation. In dissecting the mechanisms 
driving follicle miniaturisation, we have looked again into the 20th 
century literature to reprise the excellent work of such authors as, 
Van Scott9 Noback10 Arao7 Headington,11 Kligman,12 Latannand,13 
Montagna,14 Parakkal,15 Pinkus8,16 and Uno.17
2  |  BACKGROUND— TR ACKING HAIR 
FOLLICLE MINIATURISATION
It is generally accepted that a scalp hair follicle cyclically reproduces 
itself so as to maintain complete scalp coverage. Each hair cycle 
transition appears to be heralded by a change in the dynamics of 
the cycle to arrive at a new steady state. In balding, this initially in-
cludes a shortened cycle length with slowing down of daily growth 
rates without any significant change in hair diameter followed by 
a progressive regression through an “intermediate” stage, that ul-
timately leads to a stable miniaturised or transformed vellus- like 
follicle4,18 even before the clinician can perceive reduced scalp cov-
erage, terminal hair (diameters > 60 µm) decrease (Figure S1). The 
earliest measurements in affected follicles involve a shortening of 
the anagen phase, an increase in telogen (shed) hairs and, in par-
ticular, those telogen club hairs ≤30 mm in length, a reduced rate of 
hair growth, followed by a reduction in hair diameter.19– 21 From the 
clinical point of view, a substantial amount of individual hair follicle 
regression is required before noticeable hair loss is perceived by cli-
nicians (>15%19).
We present herein our opinion that current treatments do not 
reverse miniaturisation; that their success is due to preventing com-
plete regression and maintaining a prolonged productive phase in 
terminal follicles not yet irreversibly miniaturised.5 However, if re-
versing the miniaturisation process is the ultimate research objec-
tive to provide an effective and improved treatment for PHL, then 
the following fundamental questions of the miniaturisation process 
itself are raised:
1. Are those miniaturised hairs (≤40 µm in diameter, ≤30 mm in 
length) found in balding subjects produced by the same vellus 
hair follicles that we observe in healthy non- balding scalps? If 
so, is there any means to non- invasively differentiate between 
these two sub- populations in order to understand miniaturisation 
in PHL?
2. What might be preventing miniaturised hair follicles from being 
converted back to their formal terminal hair status?
2.1  |  A brief history lesson into anatomical— clinical 
correlations and the significance of structure of the 
follicular unit
The tradition of medical schools took several centuries before 
realising that human hair follicles were worth some “academic” 
consideration with biological and clinical implications. Historical 
changes that occur in common baldness in men were qualified by 
Duhring as early as 1883 as a change from “perfect hair” being re-
placed by “imperfect hair”.22 We will also mention later that the 
same author already reported that hair follicles were surrounded 
by an elastic “basket,” a somewhat neglected network. The pro-
cess of decreased “perfection” was nicely described in 1958 by Van 
Scott9 “as a progressive diminution in the size of terminal hairs.” In 
the 1960s, the prevailing view “that balding in men results from the 
metamorphosis of hair follicles from terminal to vellus,” a supposi-
tion supported in 1967 by Uno et al.23 In 1951, Noback10 “classified 
the vellus hair as one in which the follicle has no erectile tissue.” 
This was later referred to by Uno et.al and others, who were of the 
view that “vellus type" hairs that develop from terminal hair dur-
ing the balding process may still have wisps of arrector pili mus-
cle (APM) attached to them.23,24 Danforth (1939) reported “vellus 
hair follicles of the forehead undergo no changes from childhood 
to old age”.25 These early seemingly forgotten observations may 
provide insights into the miniaturisation of terminal hairs to “vellus- 
like hairs” or what we refer to as miniaturised hairs and their his-
tological identification through APM remnants. The histochemistry 
methods used, including the detection of elastin, is also important 
in interpreting the architecture, as APM attachment site to follicles 
is marked using elastin staining and the APM in miniaturised follicles 
retains its attachment to the stelae.13 It is not yet clear whether the 
loss of attachment of the APM is “causal” in follicle miniaturisation 
but was also described by Torkamani et al where they used 3D mor-
phometry to show that vellus- like hairs were no longer attached, in 
contrast to follicles in alopecia areata where APM attachment was 
maintained.26
2.2  |  Miniaturised hairs on the scalp do not 
transition back to terminal hairs with treatment
Numerous studies have attempted to define vellus hairs by uti-
lising hair diameters ≤30 µm (biopsies) and ≤40 µm (non- and 
semi- invasive methods).27– 29 From our investigations, a validated, 
quantitative parameter for a vellus hair was determined and a 
working classification established; Table S1. Thus, a hair ≤40 µm 
in diameter and ≤30 mm in length is that of a vellus or vellus- like 
hair. This definition has been employed in unit area trichogram 
evaluations to characterise miniaturising terminal hairs in MPHL 
and FPHL studies.19,30– 32 Having revisited the concept that in PHL 
there are both vellus and vellus- like (miniaturised) follicles, we 
demonstrate that the miniaturised follicle itself appears rather sta-
ble with time, once formed (although eventual deletion has been 
reported33). Although their proportion increases in untreated PHL 
(Table 1), this vellus- like population appears to be unaffected by 
hair growth treatments.4,5,34,35 We illustrate this with our UAT 
findings in men treated with topical 3% minoxidil + anti- androgens 
and oral finasteride (1.25 mg) for 12 months, Table 2. As well as 
showing that the number of vellus- like hairs remains stable, the 
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number of short (≤30 mm club hairs) decreases with treatment, 
suggesting that the increase in hair growth comes from increase in 
hair growth duration, not a decrease in vellus- like hairs, suggesting 
rescue of intermediate hair follicles and/or activation of follicles in 
kenogen.6 The point at which miniaturisation becomes inevitable 
was observed when the terminal hair diameter in actively chang-
ing FPHL patients was ≤50 µm.31 Recent research 36 provides a 
huge database as evidence of many years’ worth of clinical data 
and clearly shows that the terminal follicle goes through a dynamic 
transition with shorter anagen cycles, still producing a hair of sig-
nificant diameter, but with bulbs seated above the dermal adipose 
layer, and suggests that subsequent decrease in terminal hair di-
ameter from >60 µm to between 40 and 50 µm might be the point 
at which miniaturisation of a terminal hair follicle becomes irre-
versible. In over 20 years of treating MPHL with topical minoxidil, 
anti- androgens and oral finasteride, using unit area trichograms 
(UAT) and contrast- enhanced- phototrichograms, we have found 
find no change in the absolute vellus- like hair population, sug-
gesting “vellus- like” hairs can be stabilised but not reversed with 
current treatments. Furthermore, while treatment maintained or 
improved total hair/cm2, increased anagen hair/cm2, and hairs able 
to grow longer than 30 mm in length/cm2, such transformations 
are not achieved by reversing hair follicle miniaturisation, implying 
rescue of follicles not yet miniaturised or activation of kenogen6 
or “empty” follicles in telogen raises an intriguing question; what is 
preventing the reversal of miniaturisation?
2.3  |  Are Arao- Perkins elastin- like bodies the 
forgotten aetiology?
Following the description by Duhring in 1883 that an elastic 
basket contained the hair follicle,22 Tatsuyoshi Arao and Edwin 
Perkins7 described the complex and intricate elastin fibre deposi-
tion around hair follicles; with the key features being the presence 
of a delicate elastin filament network at the intersection of the ar-
rector pili muscle and the outer root sheath, and a knot of elastin- 
like fibres in the base of the dermal papilla (DP), referred to as 
an “elastin- like” body owing to the differences in staining colours 
observed with the orcein- haematoxylin stain used. This led to the 
term Arao- Perkins (AP) body and although being mentioned in the 
hair biology literature, notably for this review by Pinkus (1978)8 in 
relation to follicle miniaturisation in pattern hair loss, few citations 
have appeared since. In 2016, Cranwell & Sinclair reference the 
Pinkus paper but make no comment on the dense elastic tissue 
deposited beneath the follicle after each cycle, which might ex-
plain the irreversibility of follicle miniaturisation.24 The potential 
and significant implications of the Pinkus findings appear to have 
TA B L E  1  Unit area trichogram changes in frontal hair variables of untreated men exhibiting male pattern hair loss (MPHL) over 12 months 
and 24 months, values at T- 12 and T- 24 were compared with their baseline T- 0 values (Mean ± SD)
Frontal Area (Mean ± SD) Time – 0 (n = 22) Time −12 months
Total Hair/cm2 (Range) 230 ± 54 (144– 346) **215 ± 50 (140– 330)
a Vellus- Like Hair/cm2 (Range) 35 ± 18 (4– 119) *41 ± 20 (6– 110)
Anagen Hair/cm2 (Range) 147 ± 45 (58– 239) ***131 ± 48 (43– 244)
Frontal Area (Mean ± SD) Time– 0 (n = 10) Time −24 months
Total Hair/cm2 (Range) 226 ± 41 (159– 311) **199 ± 30 (129– 238)
a Vellus - Like Hair/cm2 (Range) 50 ± 30 (21– 87) *63 ± 31 (27– 111)
Anagen Hair/cm2 (Range) 120 ± 28 (80– 164) **96 ± 20 (68– 128)
Abbreviation: SD, standard deviation.
Student's t test (paired samples) – 
aVellus- like in these cases would reflect follicle miniaturisation and the resident normal vellus hair.
*(p < 0.05– 1 tail); **(p < 0.01); ***(p < 0.001).
TA B L E  2  Unit area trichogram changes in hair variables in 30 men exhibiting MPHL treated with topical 3% minoxidil + anti- androgens 
and oral finasteride (1.25 mg) for 12 months









Total Hair Density/cm2 196 ± 77 **233 ± 75 37 ± 29 **p < 0.0001
Anagen Hair/cm2 130 ± 53 **167 ± 61 37 ± 32 **p < 0.0001
§Vellus- Like Hair/cm2 34 ± 25 37 ± 27 3 ± 22 NS
Telogen Hair ≤30 mm/cm2 36 ± 25 29 ± 27 −7 ± 19 *p < 0.05
Student's t test (paired samples)— NS, not significant; * p < 0.05, **p < 0.0001, SD, standard deviation: §Vellus- like hairs reflect follicle miniaturisation, 
and this population is not influenced by treatment. Treatment resulted in a decrease in telogen hair ≤30 mm per cm2, indicating longer growing hairs 
due to an extended anagen phase. However, given the absolute increase in hairs per cm2 but no change in the absolute vellus- like hair population, 
reactivation of the dormant (kenogen) hair phase, is the most likely cause for the increased hair growth observed in the medical treatment of PHL.
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been overlooked— even Pinkus himself noted 'Preceding observ-
ers had only scant attention to elastic fibres and thereby missed 
significant features of diagnostic and pathogenetic importance';16 
little has changed since then.
Here, we re- examine the significance of the follicle elastin archi-
tecture in relation to changes in balding scalp, particularly in rela-
tion to the terminal to vellus transition in follicle miniaturisation. As 
stated above, the so- called ‘terminal to vellus’ transition implies that 
the balding vellus follicle is the same as a true vellus follicle. We, and 
others before us, believe this is not the case. In an excellent series 
of papers on the balding macaque, Hideo Uno described the minia-
turised follicles as “transformed vellus follicles” and distinguishable 
from scalp vellus follicles unchanged since childhood.17,37 This is also 
confirmed in human13 and shown in Figure 1. Where the vellus folli-
cle clearly does not have an arrector pili muscle attached. Employing 
elastin staining, Uno clearly distinguishes true vellus scalp follicles as 
having no arrector pili muscle (APM)23 whereas transformed vellus- 
like follicles either retain attachment or evidence of the terminal fol-
licle APM being close by [13].
Elastin stains are widely used in hair histopathology, where such 
stains can be helpful in diagnosis between scarring and non- scarring 
alopecia, importantly by differentiating between a follicular scar and 
a follicular streamer underlying a regressed follicle.38,39
The types of stain used include Verhoeff- Van Gieson, also known 
as elastic Van Gieson stain (EVG)38 and acid alcoholic orcein, claimed 
by Pinkus to be able to differentiate types of elastin.7,8 These studies 
conclude that there is a fine elastic fibre network surrounding the 
anagen hair follicle, not only in human scalp as originally described 
by Duhring in 188322 but also in the macaque.23,37 Such staining 
is described as a “coat” of fine elastic fibres at the follicle isthmus, 
relatively less in the connective tissue sheath and an elastic fibre 
bundle or basket at the base of the dermal papilla. Arao7 noted that 
the elastin- like body in the DP was more developed in young versus 
older adults, and, as Arao quoted “the most beautiful, finest struc-
tures of the elastin filaments are formed at puberty” suggested a 
physiological “maturation process” and/or an intimate relationship 
to androgen action on the hair follicle? So, what is the role of the 
elastic basket surrounding the hair bulb and why is the elastin body 
of Arao and Perkins so relevant in modified hair cycling occurring in 
pattern hair loss?
Pattern balding is generally associated with mild inflammation 
and fibrosis40 and the conversion of terminal follicles to smaller 
“vellus- like” follicles that reside in the upper dermis, that classically 
involves multiple anagen to catagen to telogen conversions.11,12,41 
However, Whiting, using scalp biopsies theorised that miniaturisation 
could happen in one single hair cycle.27 While miniaturisation might 
have occurred due to rapid cycling over a period of 12– 18 months,33 
but within one cycle is difficult to accept as catastrophic follicular 
changes would be required. Understanding the role and fate of the 
follicular micro- environment and especially the extracellular matrix 
(ECM) in catagen is important, as is the role of the inflammatory 
component40,42– 44 and further investigations are needed.
In the absence of balding, the AP elastin body is observed at 
the base of the DP in anagen and, apparently, does not impede the 
growth of the next terminal anagen follicle (Figure 2A, C) and the 
elasticity of the basket might be involved in determining the depth 
to which an anagen bulb descends. How the follicle “knows” when 
to stop descending is not known. While Arao and Perkins7 showed 
variability of the AP body with age in their brief reports, perhaps of 
utmost interest was the observation by Pinkus8 who detected a dis-
tinct ladder- like pattern of AP bodies in the follicle streamer under 
regressed follicles in balding, with AP bodies seemingly a permanent 
marker of the previous hair cycle in follicles undergoing miniaturisa-
tion, Figure 2B. As the normal catagen process in non- bald subjects 
does not leave a “mark” in the form of an AP elastin- like body in 
the follicle streamer, we propose that there must be a system that 
degrades and resorbs elastic tissue remnants of a previous cycle, 
removing an impediment to return to terminal anagen growth. So, 
F I G U R E  1  Human scalp H&E. Natural vellus follicle is shown 
without an arrector pili muscle and its bulb does not extend beyond 
the level of the sebaceous duct in the adjacent terminal hair follicle, 
as illustrated by the dotted line. Scale bar 100 µm
    |  5RUSHTON eT al.
do changes in elastic tissues contribute to, or just mark cyclic alter-
ations in balding?
3  |  HYPOTHESIS
We hypothesise that the lack of catabolic capabilities and/or al-
tered deposition of elastic tissue during follicle miniaturisation 
in balding represents a type of elastosis— damaging the tissue 
and preventing new terminal hair growth. We speculate that in 
the hair follicle in balding, this process involves androgen action 
and thus have examined what is known about androgen- mediated 
changes in ECM and elastic tissues in particular. The transforma-
tion of a terminal anagen follicle from anagen to telogen involves 
remarkable tissue remodelling over a short few days or weeks, 
with two thirds of the follicle regressing during catagen.15,45 The 
earliest hair biologists noted structural changes to the connective 
tissue sheath and “pleating” of the basal lamina,12,15,39 and how-
ever, the significance of changes to elastin during catagen has not 
been studied in detail, so the observations made by Pinkus in the 
1970s of the elastic body ladder8,16 have not been reexamined in 
relation to catagen in follicle miniaturisation. It is well known that 
transforming- growth- factor beta (TGFβ- 1) is increased in cata-
gen and drives catagen.46,47 It is also understood that an effect 
of androgens on shortening the hair cycle may also be mediated 
by TGFβ production by the DP cells.48,49 TGFβ is also known to 
increase ECM turnover, and in tissues where elastin is an impor-
tant component, the effects of TGFβ have been shown to act tran-
scriptionally to increase elastin synthesis.50
Thus, the “Arao Perkins” body as a marker of the hair cycle as 
seen in miniaturising follicles as a “ladder” of insoluble elastic tissue, 
may in fact, reflect a marker of androgen action on the follicle in suc-
cessive cycles? This, in turn, may help provide a mechanism of anti- 
androgen action in arresting hair loss by preventing the abnormal 
deposition of insoluble elastin and explain the finding of Hamilton3 
in 1942, that androgen ablation in castrated balding males, averted 
progression of the balding process.
Given that there is also an elastic network surrounding the 
anagen hair follicle (as described herein), we also might speculate 
whether there is a positive role for elastic component in the imme-
diate surrounding of the hair roots in, (i) helping the catagen follicle 
mechanically regress? (ii) facilitating the increase in anagen density 
with pregnancy reflecting hormonally induced circulation of growth 
factors and enzymes that help in relaxation of collagen- elastic fi-
bres (elastases and collagenases) that may help in relaxation of any 
fibrotic- elastotic barriers that prevent undue lateral or deeper follic-
ular extension, (iii) the intriguing possibility that minoxidil might act 
on hair growth through its actions on smooth muscle type cells to 
increase elastin production, as in aorta,51 and (iv) the lack of elastin 
in the stelae is indicative of scarring alopecia,52 suggesting loss of 
the elastic network is part of the loss of follicle tissues, indicating its 
importance to normal hair structure.
F I G U R E  2  Elastin staining in neck and immediately below a terminal anagen hair follicle in human scalp A, C, and in the stelae beneath, 
a miniaturised hair follicle in human scalp showing several elastic “Arao- Perkins” bodies distributed as a ladder, B. The image in A shows a 
terminal anagen HF stained for elastin using orcein- haematoxylin in iodised ferric chloride, counterstained with metanil yellow, showing the 
elastin- containing “plug” at the base of the anagen follicle. (Reproduced with permission from Arao and Perkins 1967; Reference [7], ×100). 
B, C show elastin staining using acid alcoholic orcein and Giemsa solutions as described by Pinkus 1978 and reproduced from reference [8] 
with permission. B × 100, C × 200
(a) (b) (c)
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4  |  OPEN QUESTIONS AND HOW TO 
ANSWER THESE
We ask the question “Are Arao- Perkins elastin bodies, containing 
abnormally deposited elastin, preventing the reversal of hair folli-
cle miniaturisation in female and male pattern hair loss?” In order to 
explore this, we propose that scalp tissue from males and females 
with pattern hair loss is stained using both the histochemical stains 
as used originally, but also complimented with antibody staining for 
both elastin and collagen. The lysyl oxidase (LOX) family encodes 
copper- dependent amine oxidases that are important in determining 
the tensile strength and structural integrity of connective tissues, 
including skin, by catalysing the crosslinking of elastin or collagen.53 
LOX functions in the organisation of the extracellular matrix in the 
ovary under the influence of hormonal activity54,55 and LOX with 
TGFβ regulates elastin gene expression in dermal fibroblasts.56 We 
also consider other fibrotic disorders, such as idiopathic pulmonary 
fibrosis (IPF) and kidney disease that also involve alteration in elastin 
deposition under the influence of TGFβ and LOX. IPF is associated 
with elevated elastin- collagen crosslinking and activation of myofi-
broblasts— a cell type that forms the follicle connective tissue sheath 
(CTS). The extracellular matrix exhibits a loss of elasticity and in the 
lung, this equated to loss of tissue function.57 Kidney disease fibrosis 
is also associated with greater crosslinking of the collagen and elas-
tin fibres due to elevation of LOX. Techniques used in renal disease 
pathology include elastin imaging58 so comparison of the follicle in 
AGA and kidney would be a worthy exercise, not least as these two 
organs have already been compared recently in this journal.59
In future studies, particular attention needs to be made to an 
examination of the changes in stelae under follicles that are under-
going miniaturisation60 to seek out the “Arao- Perkins” bodies and 
to characterise them using modern molecular methods and charac-
terising this particular type of fibrosis. Strategies such as expanding 
the size of the DP to reverse miniaturisation61 also should consider 
whether the Arao- Perkins elastin body may remain an impediment 
to efficacy. A molecular approach is also suggested to understand 
androgen action on fibroblasts isolated from the DP, CTS and der-
mis in relation to production and metabolism/crosslinking of elas-
tin, at both gene expression and protein modification levels. Finally, 
functional studies to examine key controls in signalling pathways to 
elastin gene expression in scalp skin should yield targets for future 
therapeutic intervention, as recently suggested for Gamma amino-
butyric acid (GABA) action in human dermal fibroblasts.62
5  |  CONCLUSION AND PERSPEC TIVES
We hope that this journey back in time, looking at the past lessons 
from eminent hair researchers, will in future lead to the identification 
of new treatment solutions to “unblock” the reversal of hair minia-
turisation, focusing on abnormal elastin deposition as the cause of a 
regenerative “block.” New regeneration treatments, such as cell ther-
apy,61 are proposed to target what might be considered to be failing 
terminal follicles prior to full miniaturisation. We predict that future 
research into the role of the elastin body in follicle biology might de-
liver a new adjuvant to current and future therapeutics to help res-
cue and/or maintain the optimal follicle size, structure and function 
of terminal follicles and promote clinically useful hair growth.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
Figure S1 Hair types (terminal, intermediate, miniaturised with 
the vellus- like and nano hair) with increasing severity of PHL. 
(Reproduced with permission from the publisher)s1
Supplementary Material TABLE S1 Absolute parameters for the 
hair variables obtained with the Unit Area Trichogram (UAT)s3,s4 in 
20 normal male and 20 normal female Caucasian subjects aged be-
tween 20 and 30 years
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